MRUS 241220 50.00C (MRUS241220C50000) Stock Options, News & Quotes

US OptionsDetailed Quotes

MRUS241220C50000

Watchlist

1.15
-1.81-61.15%

15min DelayClose Dec 3 16:00 ET

1.60High1.15Low

Intraday

5D
Daily

News

A Quick Look at Today's Ratings for Merus(MRUS.US), With a Forecast Between $67 to $100
Moomoo NewsDec 3 08:00 ET · Ratings
Strategic Partnership and Drug Approval Propel Merus to a Buy Rating With $67 Target
TipRanksDec 3 07:05 ET · Ratings
Merus Price Target Lowered to $109 From $111 at Guggenheim
TipRanksDec 3 06:45 ET
Express News | Merus NV : Guggenheim Cuts Target Price to $109 From $111
ReutersDec 3 06:18 ET
Buy Rating Affirmed for Merus: Strong Efficacy and Survival Data Bolster Confidence in Petosemtamab
TipRanksDec 3 01:46 ET
Merus Rises 10% Following Updated Phase 2 Data on Petosemtamab for Head and Neck Cancer
Seeking AlphaDec 2 15:02 ET

Comments

TrendTrader

May 24 13:26

Nice recovery. Scaling in

$Merus (MRUS.US)$

frankinglily

Apr 1 03:50

Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:

$SPDR S&P Biotech ETF (XBI.US)$
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...

Moomoo AI

Jan 9 05:10

Merus' high P/S ratio is worrisome due to underwhelming revenue forecasts. The company's declining revenue growth and below-industry growth predictions may cause a drop in the P/S ratio, risking shareholders' investments.

There's Reason For Concern Over Merus N.V.'s (NASDAQ:MRUS) Massive 39% Price Jump

Analysts Notebook

Dec 27, 2023 04:18

Columns Biotech Outlook 2024: Analysts Believe the Biotech Sector is Poised for Recovery Next Year

Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF (XBI.US)$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index (.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...

71504759

Jan 7, 2021 23:19

$Merus (MRUS.US)$ 71.55% is institutions owned, don't sell for cheap, at least 30.

Stocks & Markets Analysis